Moyamoya Disease Market Players:
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Boston Scientific Corporation
- Johnson & Johnson Services, Inc.
- Valenta Pharmaceuticals Company
- Novartis AG
- Sanofi-Aventis Groupe
- AbbVie Inc.
- Elli Lilly and Company
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of moyamoya disease is evaluated at USD 1.54 billion.
The global moyamoya disease market size was worth over USD 1.46 billion in 2025 and is poised to grow at a CAGR of around 5.8%, reaching USD 2.57 billion revenue by 2035.
By 2035, North America in the moyamoya disease drugs market is expected to secure a 33% revenue share, underpinned by the development of novel and cutting-edge technology in the region.
Key players in the market include Merck & Co., Inc., Siemens Healthcare GmbH, Boston Scientific Corporation, Johnson & Johnson Services, Inc., Valenta Pharmaceuticals Company, Novartis AG, Sanofi-Aventis Groupe, AbbVie Inc., Elli Lilly and Company.
